^
    2d
    Sunitinib or Cediranib for Alveolar Soft Part Sarcoma (clinicaltrials.gov)
    P2, N=34, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed
    Trial completion
    |
    sunitinib • Recentin (cediranib) • Leukine (sargramostim) • Neupogen (filgrastim) • loperamide
    4d
    Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=30, Recruiting, University of Washington | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • Truxima (rituximab-abbs) • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Neulasta (pegfilgrastim) • Mabtas (rituximab biosimilar) • Neupogen (filgrastim)
    8d
    AML16: A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=206, Active, not recruiting, St. Jude Children's Research Hospital | Trial primary completion date: Jun 2025 --> Sep 2025
    Trial primary completion date
    |
    sorafenib • azacitidine • etoposide IV • decitabine • daunorubicin • idarubicin hydrochloride • mitoxantrone • fludarabine IV • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Neupogen (filgrastim) • dexrazoxane
    8d
    PALETTE: Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial (clinicaltrials.gov)
    P2, N=2000, Not yet recruiting, Assistance Publique - Hôpitaux de Paris | Phase classification: P3 --> P2 | Trial completion date: Apr 2032 --> May 2031 | Trial primary completion date: May 2029 --> Jun 2028
    Phase classification • Trial completion date • Trial primary completion date • Pan tumor
    |
    Actemra IV (tocilizumab) • Kineret (anakinra) • Neupogen (filgrastim)
    9d
    A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=47, Not yet recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Jan 2027 | Initiation date: Oct 2025 --> Apr 2026 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Inqovi (decitabine/cedazuridine) • Neupogen (filgrastim)
    9d
    SELCLAX: Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=37, Active, not recruiting, St. Jude Children's Research Hospital | Trial completion date: Feb 2026 --> Sep 2027
    Trial completion date
    |
    Venclexta (venetoclax) • cytarabine • Xpovio (selinexor) • methotrexate • fludarabine IV • Neupogen (filgrastim)
    9d
    SATROPIN: Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/HER2- Breast Cancer (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, MedSIR
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    Trodelvy (sacituzumab govitecan-hziy) • Neupogen (filgrastim)
    12d
    Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease (clinicaltrials.gov)
    P2, N=10, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed
    Trial completion
    |
    Imbruvica (ibrutinib) • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • Noxafil (posaconazole)
    23d
    Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma (clinicaltrials.gov)
    P2, N=34, Not yet recruiting, Abramson Cancer Center at Penn Medicine | Initiation date: Nov 2025 --> Apr 2026
    Trial initiation date
    |
    docetaxel • 5-fluorouracil • oxaliplatin • leucovorin calcium • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • sturlimogene erparepvec (RP2)
    1m
    FLAG with Bortezomib in Children and Adolescents with Relapsed/Refractory Acute Myeloid Leukemia in a Resource-Limited Setting: A Single-Center Experience from India. (PubMed, South Asian J Cancer)
    The present study aimed to evaluate the impact, challenges, and outcome by adding bortezomib to the FLAG (fludarabine, cytarabine, and filgrastim) regimen in these populations in a resource-constraint setting...Sorafenib ( n  = 1) and midostaurin ( n  = 2) were given along with chemotherapy for children with FLT3 mutations...At the last follow-up, three (23.08%) patients are alive. FLAG-bortezomib regimen could help in pediatric and adolescent relapsed AML to achieve a remission comparable with other regimen in low- and middle-income countries, highlighting its potential.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3 mutation
    |
    sorafenib • cytarabine • bortezomib • midostaurin • fludarabine IV • Neupogen (filgrastim)
    1m
    Early CytoSorb Hemoadsorption in a Neutropenic Acute Myeloid Leukemia Patient with Carbapenem-Resistant Pseudomonas Septic Shock and ARDS. (PubMed, Diseases)
    Microbiological clearance of CRPA was not achieved; given confirmed colistin susceptibility and unknown carbapenemase mechanism, a salvage combination of colistin plus ceftazidime-avibactam was employed...Observed transient changes occurred amid simultaneous interventions (broad-spectrum antibiotics, CRRT, prone ventilation, corticosteroids, and filgrastim), precluding attribution to any single therapy, including CytoSorb...Alternative tetracycline-based combinations were reviewed but not adopted under our center's salvage protocol for this XDR presentation. Future studies are warranted to clarify its clinical benefit and optimal timing in this population.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha)
    |
    Neupogen (filgrastim)
    2ms
    Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft (clinicaltrials.gov)
    P1, N=60, Recruiting, Stanford University | Trial completion date: Dec 2025 --> Nov 2027 | Trial primary completion date: Dec 2025 --> Nov 2027
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    Jakafi (ruxolitinib) • cyclophosphamide • melphalan • fludarabine IV • thiotepa • Neupogen (filgrastim) • plerixafor